Rationale and Design of the Enoximone Clinical Trials Program

Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment options, such as cardiac transplantation and mechanical devices, a...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of cardiac failure 2005-12, Vol.11 (9), p.659-669
Main Authors:	Lowes, Brian D., Shakar, Simon F., Metra, Marco, Feldman, Arthur M., Eichhorn, Eric, Freytag, J. William, Gerber, Michael J., Liard, Jean-Francois, Hartman, Craig, Gorczynski, Rick, Evans, Gwyn, Linseman, Jennifer V., Stewart, Jennifer, Robertson, Alastair D., Roecker, Ellen B., Demets, David L., Bristow, Michael R.
Format:	Article
Language:	eng
Subjects:	Administration, Oral Cardiotonic Agents - administration & dosage Cardiotonic Agents - pharmacokinetics Cardiotonic Agents - therapeutic use Chronic heart failure Clinical Trials, Phase II as Topic - methods Clinical Trials, Phase III as Topic - methods Dose-Response Relationship, Drug Double-Blind Method Enoximone Enoximone - administration & dosage Enoximone - pharmacokinetics Enoximone - therapeutic use Heart Failure - drug therapy Hospitalization Humans Inotrope therapy Multicenter Studies as Topic Phosphodiesterase Inhibitors - administration & dosage Phosphodiesterase Inhibitors - pharmacokinetics Phosphodiesterase Inhibitors - therapeutic use Randomized Controlled Trials as Topic - methods Research Design Treatment Outcome Type III phosphodiesterase inhibitors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment options, such as cardiac transplantation and mechanical devices, are severely limited by availability and cost. Short-term Phase II clinical trials suggest that low-dose oral inotropic therapy with enoximone may improve hemodynamics and exercise capacity, without adversely affecting mortality, in selected subjects with advanced chronic heart failure. Based on these data, the ability of enoximone to deliver safe and efficacious palliative treatment of advanced/ultra-advanced chronic heart failure is being evaluated in Phase III clinical trials. The Enoximone Clinical Trials Program is a series of 4 clinical trials designed to evaluate the safety and efficacy of oral enoximone in advanced chronic heart failure. ESSENTIAL I and II (The Studies of Oral Enoximone Therapy in Advanced Heart Failure) will investigate the effects of oral enoximone on all-cause mortality and cardiovascular hospitalization, submaximal exercise capacity, and quality of life in subjects with New York Heart Association Class III/IV chronic heart failure. EMOTE (Oral Enoximone in Intravenous Inotrope-Dependent Subjects) will evaluate the potential of oral enoximone to wean subjects with ultra-advanced chronic heart failure from chronic intravenous inotropic therapy to which they have been shown to be dependent. EMPOWER (Enoximone Plus Extended-Release Metoprolol Succinate in Subjects with Advanced Chronic Heart Failure) will explore the potential of enoximone to increase the tolerability of continuous release metoprolol in subjects shown previously to be hemodynamically intolerant to β-blocker treatment. These studies are Phase III, multicenter, randomized, double-blinded, placebo-controlled trials designed to test the general hypothesis that chronic oral administration of low doses of enoximone can produce beneficial effects in subjects with advanced or ultra-advanced chronic heart failure.
ISSN:	1071-9164 1532-8414